Markedly increased incidence and improved survival of testicular cancer in the Netherlands

Figures & data

Figure 1. Three-year moving average European standardized (ESR) incidence and mortality rates for testicular cancer in the Netherlands 1970–2009 per 100 000 person-years.

(Incidence rates 1970–1989: data from the Eindhoven Cancer Registry; Incidence rates 1990–2009: data from the Netherlands Cancer Registry; mortality rates 1970–2009: Statistics Netherlands).

Table I. Patient and tumor characteristics of testicular cancer patients included in this study.

	1970–1979*		1980–1988*		1989–1999		2000–2009		Total
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)
Number of patients	122		166		4484		5900		10 672
Age at diagnosis
0–14 years	3	2%	1	< 1%	53	1%	24	< 1%	81	< 1%
15–29 years	39	32%	73	44%	1638	37%	2078	35%	3828	36%
30–44 years	51	42%	57	34%	2042	46%	2838	48%	4988	47%
45–60 years	19	16%	24	15%	533	12%	744	13%	1320	12%
≥ 60 years	10	8%	11	7%	218	5%	219	4%	458	4%
Histology
Seminoma	68	56%	78	47%	2327	52%	3108	53%	5581	52%
Non-seminoma	48	39%	81	49%	2089	47%	2708	46%	4926	46%
Other/NOS	6	5%	7	4%	68	2%	84	1%	165	1%
Stage at diagnosis of patients with a seminoma
Localized	24	35%	61	78%	1851	80%	2538	82%	4474	80%
Regional lymph nodes	4	6%	10	13%	337	14%	429	14%	780	14%
Distant metastasis	3	4%	3	4%	113	5%	135	4%	254	5%
Unknown	37	54%	4	5%	26	1%	6	< 1%	73	1%
Stage at diagnosis of patients with a non-seminoma
Localized	19	40%	39	48%	1191	57%	1683	62%	2932	60%
Regional lymph nodes	6	13%	16	20%	446	21%	522	19%	990	20%
Distant metastasis	1	2%	18	22%	437	21%	490	18%	946	19%
Unknown	22	46%	8	10%	15	< 1%	13	< 1%	58	1%

NOS, not otherwise specified.

* For the period 1970–1988 only data of the Eindhoven cancer registry was available.

Figure 2. Three-year moving average of age-specific European standardized (ESR) incidence rates of seminoma (Figure 2a) and non-seminoma (Figure 2b) in the Netherlands.

Figure 3. Three-year moving average stage-specific European standardized (ESR) incidence rates per 100 000 person-years for seminoma (Figure 3a) and non-seminoma (Figure 3b) testicular cancer in the Netherlands 1989–2009.

Figure 4. Treatment of testicular cancer in the Netherlands, according to period of diagnosis, histology and stage.

Table II. Five-year relative survival with 95% confidence intervals for patients with testicular cancer in the Netherlands according to period of diagnosis, age and histology and stage groups.

	1989–1993	1994–1998	1999–2003	2004–2009	p-value trend
Total	95 (94–96)	95 (94–96)	96 (95–97)	98 (97–98)	< 0.0001
Age (years)
15–29	95 (93–97)	95 (93–96)	96 (95–97)	98 (96–98)	< 0.01
30–44	96 (94–97)	97 (95–98)	97 (96–98)	98 (97–99)	0.02
45–59	94 (89–97)	93 (89–96)	96 (93–99)	96 (92–98)	0.05
≥ 60	85 (72–96)	89 (77–99)	87 (76–96)	96 (82–104)	0.86
Seminoma stage
Localized	99 (97–100)	99 (97–100)	99 (98–100)	101 (100–101)	0.09
Regional lymph nodes	93 (87–97)	96 (91–99)	96 (92–98)	100 (97–101)	0.01
Distant metastases	73 (57–84)	83 (69–92)	87 (74–95)	88 (75–94)	0.07
Non-seminoma stage
Localized	99 (97–100)	99 (97–100)	98 (96–99)	99 (98–100)	0.91
Regional lymph nodes	97 (93–99)	94 (90–97)	98 (95–99)	94 (89–97)	0.54
Distant metastases	78 (71–83)	81 (75–85)	82 (77–86)	85 (80–90)	0.05